ArticleBMC cancer2025

Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China.

Benlong Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.